| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.17 | 0.2 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.2 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |